Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Oct 4, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, compliance
TL;DR
Genmab filed a 6-K, incorporating it into existing S-8 filings. Standard compliance update.
AI Summary
Genmab A/S filed a Form 6-K on October 4, 2024, to report information for the month of October 2024. This report is incorporated by reference into Genmab A/S's existing S-8 registration statements (File Nos. 333-232693, 333-253519, 333-262970, and 333-277273). The company is a foreign private issuer based in Denmark.
Why It Matters
This filing ensures Genmab A/S remains compliant with SEC reporting requirements for its publicly traded securities in the US, providing ongoing transparency to investors.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-013146 (filing_id) — Accession Number
- 20241004 (date) — Filing Date
- 333-232693 (registration_statement_id) — S-8 File Number
- 333-253519 (registration_statement_id) — S-8 File Number
- 333-262970 (registration_statement_id) — S-8 File Number
- 333-277273 (registration_statement_id) — S-8 File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is a report of a foreign private issuer for the month of October 2024, intended to provide information to the SEC.
Which registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is Genmab A/S's primary business classification according to the filing?
Genmab A/S is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where is Genmab A/S's principal executive office located?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Is Genmab A/S required to file an annual report on Form 20-F or 40-F?
The filing indicates that Genmab A/S files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 218 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2024-10-04 15:16:21
Filing Documents
- tmb-20241004x6k.htm (6-K) — 18KB
- tmb-20241004xex99d1.htm (EX-99.1) — 16KB
- tmb-20241004xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-013146.txt ( ) — 41KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: OCTOBER 4, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated October 4, 2024: Major Shareholder Announcement